View
May 15, 2026
Specialty Pharmaceuticals Face Access Challenges in the AI Era
In this summary, we share Insights from Asembia AXS26 on how AI, payer scrutiny, and evolving reimbursement models are reshaping market access and why specialty pharma must rethink access strategies earlier to stay ahead.
